Crizotinib

BreastfeedingPediatric
  • TRADE NAME: Xalkori (Pfizer)
  • INDICATIONS: Advanced or metastatic non-small cell lung cancer in ALK-positive patients
  • CLASS: Tyrosine kinase inhibitor
  • HALF-LIFE: 42 hours

Our database has 82 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
HAIR
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
NEUROMUSCULAR/SKELETAL
GASTROINTESTINAL/HEPATIC
RESPIRATORY
ENDOCRINE/METABOLIC
RENAL
HEMATOLOGIC
OCULAR
OTHER


Visit Informa

Click on the DRUG REVIEW ARTICLE tab (above) to see a review of crizotinib in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Page last updated 09/19/2018

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric